Podcasts about Nick Turner

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Luna Paige joins Amy MacIver with an invitation to Big Folk Africa, an opportunity for audiences to slow down and savour the story behind the song. This Sunday, 30 March 2025, The Homestead in Hout Bay will host a picnic-style showcase of five talented singer-songwriters: Luna Paige, Nick Turner, Stanley Sibande, Divine Mahara, and Avril Mkansi (Dhahabu). Big Folk Africa invites audiences to slow down and savour the story behind the song. This Sunday, 30 March 2025, The Homestead in Hout Bay will host a picnic-style showcase of five talented singer-songwriters: Luna Paige, Nick Turner, Stanley Sibande, Divine Mahara, and Avril Mkansi (Dhahabu).See omnystudio.com/listener for privacy information.

Our sponsor today is BetterHelp. For 10% off, Betterhelp.com/aitapodFeat. Nick Turner - https://www.instagram.com/nicksturners/?hl=enGiulia Rozzi - https://www.instagram.com/msgiuliarozzi/?hl=en(0:00) - Banter and marriage threads(39:25) - Best Marriage hacks thread(1:10:48) - AITA for being annoyed husband Js off to IRL people?(1:21:30) - AITA for not listening to wife and eating the wrong cookie?(1:34:04) - AITA for agreeing w mom it's pathetic wife can't cook?(1:51:55) - AITA bc I won't watch anything more complicated than a hallmark movie with my wife?BEST way to Submit a sitch or comment: https://www.reddit.com/r/AITApod/Email - amitheahole@gmail.com Join Patreon! https://patreon.com/aitapodWhat's on Patreon?- 200+ Bonus eps- NO ADS and accurate timestamps- Discord with awesome communityTikTok - https://www.tiktok.com/@aitapodInstagram - https://www.instagram.com/aita_pod/

This is the daily Tech and Business Report. Today, we're joined by Bloomberg's Nick Turner. Intel stock is up 14%, following a report that the company could be split in two.

In this episode of Careers Unwrapped, host Mark Fawcett is joined by Nick Turner, Group Chief Executive Officer at NFU Mutual, to discuss his journey from stacking shelves to leading one of the UK's major insurers, his philosophy of kind and commercial leadership, and why insurance is far more exciting than people think.

NYC Live show on Oct 22! Get your tickets: https://events.humanitix.com/the-b-o-boys-in-box-office-save-america Live show in Boston on Nov 16 with KIRK MINIHANE! Tickets: https://www.thecomedystudio.com/event/the-b-o-boys-live-with-kirk-minihane/   Remember to Rate (5 Stars), Review (Great show, blah, blah, blah) and Follow us on Apple Podcasts: https://podcasts.apple.com/us/podcast/b-o-boys-movie-box-office/id1489892648   Our AWESOME artwork was provided by the talented Ellie Skrzat. Check out her work at https://ellieskrzat.com/   Thanks to WannaBO Senior Intern Christopher for running our social media and WannaBO Intern Jack for the numbers.   E-mail us: theboboyspodcast@gmail.com   Subscribe on Youtube:   https://www.youtube.com/@theboboyspodcast   Follow us on Twitter: @TheBOBoysPod   Follow us on TikTok: @TheBOBoysPod   Subscribe to us on Substack and read our new articles: https://substack.com/@theboboys   -----

Host C.J. Sullivan recaps the NFL Cut Day aftermath and the Haarbaugh tale of the Chargers stuck in an elevator.   C.J. then begins the NFC East preview show with Cowboys Insider and comic, Nick Turner.  The rest of the division looks to be top heavy as the favored Philadelphia Eagles dwarf the NY Giants and Washington Commanders.   Finally, a Man in the Box segment about Deion Sanders and his new disdain for nicknames.   Picks with bits are for tobacco use only. JOIN the SGPN community #DegensOnlyExclusive Merch, Contests and Bonus Episodes ONLY on Patreon - https://sg.pn/patreonDiscuss with fellow degens on Discord - https://sg.pn/discordDownload The Free SGPN App - https://sgpn.appCheck out the Sports Gambling Podcast on YouTube - https://sg.pn/YouTubeCheck out our website - http://sportsgamblingpodcast.comSUPPORT us by supporting our partnersPromo code FOOTBALL - 10% off everything http://sg.pn/storeUnderdog Fantasy code SGPN - Up to $1000 in BONUS CASH - https://play.underdogfantasy.com/p-sgpnFootball Contest Proxy - Use promo code SGP to save $50 at - http://proxy.footballcontest.comRithmm - Player Props and Picks - Free 7 day trial! http://sportsgamblingpodcast.com/rithmmGametime code SGPN - Download the Gametime app, create an account, and use code SGPN for $20 off your first purchase - https://gametime.co/OddsJam - 7-day free trial and 35% off your first month subscription promo code SGPN - https://fas.st/t/yaJkJgH132 NFL Team Previews - https://www.sportsgamblingpodcast.com/2024-nfl-team-previews/  ADVERTISE with SGPNInterested in advertising? Contact sales@sgpn.ioFOLLOW The Sports Gambling Podcast On Social MediaTwitter - http://www.twitter.com/gamblingpodcastInstagram - http://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcastFOLLOW The Hosts On Social MediaSean Green - http://www.twitter.com/seantgreenRyan Kramer - http://www.twitter.com/kramercentric================================================================Gambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA) 21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)================================================================

Host C.J. Sullivan recaps the NFL Cut Day aftermath and the Haarbaugh tale of the Chargers stuck in an elevator.   C.J. then begins the NFC East preview show with Cowboys Insider and comic, Nick Turner.  The rest of the division looks to be top heavy as the favored Philadelphia Eagles dwarf the NY Giants and Washington Commanders.   Finally, a Man in the Box segment about Deion Sanders and his new disdain for nicknames.   Picks with bits are for tobacco use only. JOIN the SGPN community #DegensOnlyExclusive Merch, Contests and Bonus Episodes ONLY on Patreon - https://sg.pn/patreonDiscuss with fellow degens on Discord - https://sg.pn/discordDownload The Free SGPN App - https://sgpn.appCheck out the Sports Gambling Podcast on YouTube - https://sg.pn/YouTubeCheck out our website - http://sportsgamblingpodcast.comSUPPORT us by supporting our partnersPromo code FOOTBALL - 10% off everything http://sg.pn/storeUnderdog Fantasy code SGPN - Up to $1000 in BONUS CASH - https://play.underdogfantasy.com/p-sgpnFootball Contest Proxy - Use promo code SGP to save $50 at - http://proxy.footballcontest.comRithmm - Player Props and Picks - Free 7 day trial! http://sportsgamblingpodcast.com/rithmmGametime code SGPN - Download the Gametime app, create an account, and use code SGPN for $20 off your first purchase - https://gametime.co/OddsJam - 7-day free trial and 35% off your first month subscription promo code SGPN - https://fas.st/t/yaJkJgH132 NFL Team Previews - https://www.sportsgamblingpodcast.com/2024-nfl-team-previews/  ADVERTISE with SGPNInterested in advertising? Contact sales@sgpn.io================================================================Gambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

Folks, we're off this week to attend Patty's wedding but we've compiled our favorite dog related stories from the podcast with appearances by Nick Turner, Rob Delaney, and Luke Mones! Become a patron for weekly bonus eps and more stuff! :www.patreon.com/whatatimepod Check out our YouTube channel: https://www.youtube.com/c/whatatimetobealive Get one of our t-shirts, or other merch, using this link! https://whatatimepod.bigcartel.com/whatatimepod.com Join our Discord chat here:discord.gg/jx7rB7J @pattymo // @kathbarbadoro // @eliyudin// @whatatimepod ©2024 What A Time LLC

Shermaine Williams reports that Councillor Nick Turner speaks negatively about Caribbean people. --- Send in a voice message: https://podcasters.spotify.com/pod/show/africandiasporanews/message Support this podcast: https://podcasters.spotify.com/pod/show/africandiasporanews/support

Dive into a rollercoaster of laughter with Nick Turner as he hilariously navigates the twists and turns of embracing his curves, love life, and the joys of aging. Whether it's finding humor in fitness fiascos or the quirks of relationship dynamics, Nick's unique perspective turns everyday scenarios into comedy gold. Aging isn't just a number; it's a treasure trove of jokes waiting to be told. Don't miss out on this journey of self-discovery and laughter. Tune in for an episode that's as enlightening as it is entertaining. For more comedic gems and side-splitting episodes, sprint over to https://foqnfunny.com. Ready to ditch the ads? Jump onto FOQN Funny+ now! Love what you're hearing on FOQN Funny? Go a step further and become a member of FOQN Funny+. Enjoy exclusive perks and never-ending laughter. Join now at: https://plus.acast.com/s/foqn-funny. Hosted on Acast. See acast.com/privacy for more information.

In 2016, a handful of wireless engineers got together and decided to create the portable tool they all wish existed. Thus the WLAN Pi was born. Jerry Olla, Nick Turner, and Jiri Brejcha join the show today to talk about the evolution of the open source WLAN Pi and its current capabilities. The latest generation... Read more »

In 2016, a handful of wireless engineers got together and decided to create the portable tool they all wish existed. Thus the WLAN Pi was born. Jerry Olla, Nick Turner, and Jiri Brejcha join the show today to talk about the evolution of the open source WLAN Pi and its current capabilities. The latest generation... Read more »

In 2016, a handful of wireless engineers got together and decided to create the portable tool they all wish existed. Thus the WLAN Pi was born. Jerry Olla, Nick Turner, and Jiri Brejcha join the show today to talk about the evolution of the open source WLAN Pi and its current capabilities. The latest generation... Read more »

When everyone went scrambling to therapy during lockdown in 2020, what did the therapists think? Find out in this sweet and intimate conversation with Nick Turner, aka the experimental ambient musician Tyresta. I've had lots of musicians who are in Nick's orbit as guests, but he's the first one to really delve into the music-making process, so this could be a good intro to thinking about a genre that can get pretty heady. Find joy in the music and in this episode!Content warning: mom dying, burnout, insomnia, anxiety, modular synthesis, Acceptance and Commitment Therapy, Zen, making instrumental music ABOUT something, joy-curating practices, Suzanne Ciani & Kaitlyn Aurelia Smith's album Sunergy.If you believe in This Is Your Afterlife and want fun bonus episodes, become a patron for $5 or $15/month at patreon.com/davemaher. Follow Nick on IG at @nick__turner.Listen to and buy the newest Tyresta album, Small Hours.Preorder the new Montgomery and Turner album, Sound Is (Our) Sustenance!And if you want to book therapy with Nick, check out his Psychology Today page.Donate to the Chicago Abortion Fund via my page to provide life-saving healthcare to folks who need abortions.Follow this show on IG: @thisisyourafterlife, and get more info at thisisyourafterlife.com. Have thoughts on the show? Email thisisyourafterlifepodcast@gmail.com.Follow me @thisisdavemaher on Instagram and Twitter.All music by This Is Your Afterlife house band Lake Mary.Check out my other podcast, Genre Reveal Party!, where I analyze TV and movies with my friend, writer and cultural critic Madeline Lane-McKinley.

In the latest captivating episode of the podcast "Concerts That Made Us," Brian, sits down for an in-depth conversation with the dynamic members of The Misty Cliffs—frontman Nick Turner and drummer Nick Catto. Together, they embark on a journey through the creative process that led to the birth of their much-anticipated debut album.The discussion kicks off with the band members exploring the rich tapestry of inspiration and overarching themes that breathe life into their music. They speak candidly about the emotional depth of their songs, particularly how the universal experience of heartbreak has been a poignant source of creativity for them. The conversation takes a deeper dive as they reveal how the cyclical nature of seasonal changes has also played a significant role in shaping the mood and tone of their tracks.As the episode progresses, the two Nicks share intimate stories that highlight their personal connections to each song on the album. They discuss how their individual experiences have been woven into the music, creating a resonant and authentic sound that listeners can relate to. The influence of Cape Town, is a recurring theme in their discussion, as they talk about how the city's vibrant culture and diverse musical landscape have left an indelible mark on their sound.Reflecting on their journey so far, the band members recount some of the most memorable concerts they've performed. They delve into how these live experiences have not only helped them connect with their fans but also influenced the evolution of their music. Each concert story is a testament to the power of live music and its ability to shape an artist's career.Despite the challenges of being geographically dispersed, The Misty Cliffs are determined to continue their musical journey together. They share their excitement about planning future gigs and even tease the possibility of a Christmas album, hinting at the diverse directions their music could take in the future.Before wrapping up the episode, the conversation takes a lighter turn as the band members discuss their current musical obsessions. They express their admiration for the innovative sounds of South African musician Medici Junkies and the legendary production techniques of Rick Rubin, offering listeners a glimpse into the influences that might shape their future work.Listeners of "Concerts That Made Us" are sure to find this episode both enlightening and entertaining, as it provides a rare look behind the curtain at the creative forces driving one of the most exciting new bands on the scene, The Misty Cliffs.Find The Misty Cliffs here:https://open.spotify.com/artist/3CFW4FL5DJJeohKk1gakqO?si=i0vir4b6Twi1XwBvgi7q8AFind CTMU hereLinktreeNewsletter: https://concertsthatmadeus.aweb.page/p/f065707b-2e34-4268-8e73-94f12bd2e938Save 10% on Band Builder Academy membership by following this link https://bandbuilderacademy.com/Brian_Concerts/join and using promo code "concerts" at signup Become a member at https://plus.acast.com/s/concerts-that-made-us. Hosted on Acast. See acast.com/privacy for more information.

Pippa speaks to Nick Turner from the Misty CliffsSee omnystudio.com/listener for privacy information.

In this episode of Capital for Good we speak with Nick Turner, the president and director of the Vera Institute of Justice, where he has spearheaded the organization's work over the last decade to end overcriminalization and mass incarceration in the United States. Turner is one of the nation's most visible and important leaders on criminal legal reform – and on a broader set of equity and justice issues. We begin with some of the formative experiences that would shape Turner's lifelong commitment to justice, fairness, and understanding “how things work — or don't work — for people.” The son of Black and Filipina parents, Turner grew up in Washington, DC, attended a Quaker school with a deep service ethos — and would return to Washington after college to work with court-involved, homeless, and disconnected young people at Sasha Bruce Youthwork, a youth services organization. After Sasha Bruce, Turner says he could never “unsee” the glaring underinvestment in that community and in the potential of its young people — and would go on to pursue a career focused on the structural changes necessary to address these inequities. We discuss the complex issue of mass incarceration; the politics of fear that drive excessive policing, charging, and sentencing; the criminalization of poverty; and the deeply racial disparities and underpinnings of a legal and carceral system that would grow 700 percent between 1972 and 2009, when 2.5 million people in the United States were behind bars and half of all American families have had an immediate family member incarcerated. Turner reminds us, and the data show, that incarceration in the United States is often counterproductive. The severe disruptions and trauma that come with time behind bars can lead to a vicious cycle of instability, poverty, crime, and reincarceration. Although we have made significant progress — the number of people incarcerated is down 25 percent from 2009 — we find ourselves again in a moment when fears about crime and public safety have dampened support for important and evidenced-based criminal justice reforms. In addition to some of the better known and proven reforms (i.e., those related to bail and sentencing), Turner describes alternatives to conventional policing and incarceration — responding to mental health, housing, or substance use crises with trained specialists instead of police, community violence intervention programs — that reduce crime, deliver safety and accountability, and help shrink the jail and prison populations. We also touch on important rehabilitative efforts to improve conditions behind bars (such as education and restorative housing pilots) and ways the private sector — through changes to hiring and housing policies — can improve opportunities for people to be successful once they are released. Turner notes that despite the polarizing politics of public safety, most Americans are now “smarter” about the harmful costs of mass incarceration — younger generations particularly so — and support change. “It is possible to have public safety and justice,” he says. “People want safety, they also want solutions.” Thanks for listening! Subscribe to Capital for Good on Apple, Amazon, Google, Spotify, or wherever you get your podcasts. Drop us a line at socialenterprise@gsb.columbia.edu.  Mentioned in this episode Ending Mass Incarceration, (Vera Institute of Justice) The Prison Paradox: More Incarceration Will Not Make Us Safer, (Vera Institute of Justice) Nearly Half of Americans Have Had a Family Member Jailed, Imprisoned, (Cornell University, 2019)

We find ourselves at a moment of great challenge – and opportunity.  In this season of Capital for Good, we'll explore how the world's political, economic, and climate crises have compelled us to reimagine how leaders across the private, nonprofit, and public sectors champion social and environmental change in ways that truly advance shared prosperity and a sustainable future. This season host Georgia Levenson Keohane will speak with a dynamic line-up of leaders, including business and nonprofit leader Andrea Jung, the former CEO of Avon and current president and CEO of Grameen America; Nick Turner, the president of the Vera Institute of Justice; Pulitzer prize winner, New York Times writer, and author David Leonhardt; Sonal Shah, the CEO of the Texas Tribune; political strategist and arts and civic leader Luis Miranda; corporate and sustainability pioneer Audrey Choi; Shaun Donovan, government leader and current Enterprise Community Partners CEO; and Suzanne Nossel, CEO of PEN America, the leading human rights and free expression organization; and more!

If you're tired of restricted funding that only allocates 10% (or less) of a grant for admin and overhead, Nick Turner shares how he successfully makes a case for unrestricted grants and gifts.  Nick Vera is the CEO of the Institute of Justice, and he has dramatically grown his organization by soliciting and leveraging unrestricted gifts. In this episode, you and Nick will explore: The importance in gaining funder confidence before asking for large unrestricted grants Strategies for overcoming funder hesitancy to make unrestricted grants Tactics for setting boundaries with funders who want to be overly granular in their restrictions Similar episodes you will find useful include:  Ep 170: Challenge the Fundraising Status Quo with Sherry Quam Taylor (Apple) (Spotify) Ep 279: Standing Up for Equitable Funding Practices with Lauren Steiner (Apple) (Spotify) Links mentioned in the episode: Vera Institute of Justice Website https://www.vera.org/ Vera Institute of Justice Twitter https://twitter.com/verainstitute Vera Institute of Justice LinkedIn https://www.linkedin.com/company/verainstitute/ Vera institute of Justice Facebook https://www.facebook.com/verainstitute Vera Institute of Justice Mastodon https://mstdn.social/@verainstitute

The Nicks return together before the Labor Week break! The gang discusses Mitch McConnell's second on-camera freeze (a month after his first), the woman who cheated on her husband and lied to 911 about being raped to receive a free STD test, and a personal Active Shooter incident. Enjoy!

In episode 1537, Jack and special guest host Nick Turner are joined by writer/showrunners Alyson Levy & Alissa Nutting to discuss… The new capital of cool: Bentonville, AR?, FyreFest giving it another go, and so much more! Bentonville: The new capital of cool FYRE FESTIVAL 2.0 LISTEN: Noname - RainforestSee omnystudio.com/listener for privacy information.

It's the LPN Summer Break so please turn down the lights and abandon your family while you luxuriate in the seducing, dulcet tones of every DGWE so far. Featuring Holden McNeeley, Henry Zebrowski, Ed Larson, MJ Knefel, Marcus Parks, Seena Ghaznavi, Ben Kissel, Reid Faylor, Andrew Short, Danny Tamberelli, Jeremy Balon, Amber Nelson, Emily Flemming, Brooks Wheelan, Nick Turner, Dave Willis, Dana Snyder, Fernando Perez Leon, Kara Klenk, Geoff Adams, Adam Newman, and Jason Saenz.These Deep Dives are based on novels by Sarah J Maas. Intro music by Ryan Connor. Cover art by Jeff Nitzberg.

Peloton is looking towards a new target market as it attempts to revitalize is business. Peloton, which built its reputation on its in-home workout equipment, is coming up with a new business plan.  For more on this, KCBS Radio's Holly Quan spoke with Bloomberg Senior technology editor Nick Turner.

In episode 1508, Jack and Miles are joined by comedian, Nick Turner, to discuss… Trump Tape Full of Treason/Hillary Jokes Leaks To CNN, The Defenses of This Tape Are…Frightening, It Really is the 80s Again - COCAINE IS EVERYWHERE, Logan Paul's Energy Drink Is Basically Poison and more! Trump Tape Full of Treason/Hillary Jokes Leaks To CNN Exclusive: CNN obtains the tape of Trump's 2021 conversation about classified documents Bedminster golf club tape casts doubt on Trump account of Iran document It Really is the 80s Again - COCAINE IS EVERYWHERE Logan Paul's Energy Drink Is Basically Poison Prime drink: How KSI and Logan Paul made it so popular Prime drinks are going viral in real life. It's all about status. Why Logan Paul, KSI-backed energy drinks have triggered new health alerts for parents Teens Are Probably Drinking Too Much Caffeine LISTEN: Green House by AmindiSee omnystudio.com/listener for privacy information.

Feyre learns to take a look, it's in a book, in the library under the House of Wind; the gang heads to the Hewn City; the Archeron sisters have to decide whether Elain needs a one way ticket to the nut house. Please read up until Chapter 33! DGWE featuring Brooks Wheelan and Nick Turner.These Deep Dives are based on novels by Sarah J Maas. Intro music by Ryan Connor. Cover art by Jeff Nitzberg.

Part of their conversation is about the biggest challenge a non-technical, non-product founder faces when building software. The founder has been doing this full time since July, and their main concern is to make sure that the software they are building does not become employee tracking software. The founder has learned that the implementation, setup, and training of the software are what make it successful, and that most companies rarely get it right. Furthermore, the founder has been trying to find a product-market fit since they started the startup nine months ago and has been making cold calls to find potential customers.Key Topics:Exploring the Benefits of AI-Powered Sales AnalyticsConversation on Leveraging Slack Activity to Lead a Team ForwardConversation on Leadership, Product Development, and StartupsExploring Leadership Solutions for Frontline Leaders in Growing CompaniesExploring Leadership Development Strategies to Measure Impact and Increase ValueConversation on Listening to the Echo and Finding Market FitPivoting Outreach Strategy to Increase Product Adoption: A Conversation with a FounderConversation on Listening to the Echo and Finding Market FitIf you get value from this episode, be sure to subscribe and share the episode with your friends, as we all can benefit from more positivity and leadership in today's society.Be sure to follow Duane Dufault on all the social platforms to get daily hits of tactical advice that you can take action on right away Linkedin | Facebook | Instagram | Twitter | Youtube | TikTok

Nick Vatterott and Nick Turner are ready to get silly, hilarious, dark, and sad. The group discusses the WGA Writers Strike, listener Saadia accusing Keith of trying to kill her, and ex-Mayor/ex-Trump private attorney Rudy Giuliani being sued for forced sex, wage theft, and much more.

It's the time of year where magical faerie goo gets splattered all over Rhys, and also it's Starfall! We visit *that* Inn and the Suriel provides the hottest Night Court gossip. Please read up until Chapter 58! DGWE featuring Nick Turner and Brooks Wheelan.These Deep Dives are based on novels by Sarah J Maas. Intro music by Ryan Connor. Cover art by Jeff Nitzberg.

In this episode of The SAR Take, I sit down with Nic Turner and Ryan Morris to discuss the path to becoming a Search and Rescue Technician (SAR Tech) in the Canadian Armed Forces. Nic and Ryan make a compelling case for joining the infantry as an entry trade before becoming a SAR Tech, and they discuss the benefits and challenges of this approach.The conversation also delves into the experience of going through the Parachute phase on the SAR course and what it's like to be a SAR Tech instructor at the Canadian Forces School of Search and Rescue. Nic and Ryan share their insights and stories about the unique training and demands of this specialized profession and the rewards and satisfaction that come with it.Remember you can always reach out to thesartake@gmail.com for questions or more information.Enjoy, RESCUEPosting Season is here! If you or someone you know is heading or leaving to/from Comox, Greenwood, Gander consider telling them about some excellent Realtors who help sponsor this project. Their info can be found with a simple search or on thesartake.comNate King - Comox, BCPaul Jackman - Greenwood, NSAshley Bullen - Gander, NFLDSupport the show

The conversation discussed the core fundamentals of management and how they can be improved.He then discussed how there are two core aspects to management: team meetings and one-on-one meetings. Nick noted that at large companies, it was difficult to get managers to show up for one-on-one meetings as they prioritized customer meetings over them.Nick suggested that when working remotely, there is less randomness and spontaneity than working in the office, so it is important to be intentional with how you are managing your time with the team.This could include having one-on-one meetings with team members, leaving an hour open for customer calls, and being present with the team when they need you. Being intentional with time management is an important aspect of successful remote team management.If you get value from this episode, be sure to subscribe and share the episode with your friends, as we all can benefit from more positivity and leadership in today's society.Be sure to follow Duane Dufault on all the social platforms to get daily hits of tactical advice that you can take action on right away.

This podcast is a commentary and does not contain any copyrighted material of the reference source. We strongly recommend accessing/buying the reference source at the same time. ■Reference Source https://www.ted.com/talks/nick_turner_and_whitney_pennington_rodgers_how_to_fix_two_of_the_most_broken_systems_in_the_us ■Post on this topic (You can get FREE learning materials!) https://englist.me/160-academic-words-reference-from-nick-turner-and-whitney-pennington-rodgers-how-to-fix-two-of-the-most-broken-systems-in-the-us--ted-talk/ ■Youtube Video https://youtu.be/OLL1wiEYrfQ (All Words) https://youtu.be/TjyXjZYZsiI (Advanced Words) https://youtu.be/pBN3ta6yOzw (Quick Look) ■Top Page for Further Materials https://englist.me/ ■SNS (Please follow!)

A midweek episode where we catch up with Nick Turner. See me on tour at brookswheelan.com/dates

In episode 1425, Jack and guest co-host Matt Lieb are joined by comedian and co-host of Get Rich Nick, Nick Turner, to discuss… FBI Will Investigate Harris County Jail, More Details On That I Am Legend Sequel and more! FBI Will Investigate Harris County Jail Harris County Jail making changes after state report finds inmate died from lack of medication PREGNANT PEOPLE ARE SHACKLED AND ABUSED IN HARRIS COUNTY JAIL More Details On That I Am Legend Sequel 5 Awesome Movies Ruined By Last-Minute Changes I Lived Through Collapse. America Is Already There LISTEN: The Way the Wind Whips by Blac RabbitSee omnystudio.com/listener for privacy information.

Brooks and Turner catch up and complain about everything. But also Turner is going on tour so go see him. follow nick for tour dates: https://twitter.com/nicksturners

Did you know that Lou Pearlman was in the *blimp* business? Before he was Big Poppa he crashed his first blimp only a mile away from where the Hidenberg went down. He entire empire started with insurance fraud and was amplified by Art Garfunkel - found out way on the show. And we get a guest appearance from our writer Nick Turner to play the Name Game: Lou Pearlman artist or dot come bubble business? Listen now cause we know you want it that way. Did you know that Lou Pearlman was in the *blimp* business? Before he was Big Poppa he crashed his first blimp only a mile away from where the Hidenberg went down. He entire empire started with insurance fraud and was amplified by Art Garfunkel - found out way on the show. And we get a guest appearance from our writer Nick Turner to play the Name Game: Lou Pearlman artist or dot come bubble business? Listen now cause we know you want it that way. Follow Us:https://twitter.com/seenanowhttps://www.instagram.com/justin_williams_comedyhttps://twitter.com/arielleatyFollow the show on Discord: https://discord.gg/WRZ8zgusPTWebsite: https://fraudsters.fm/Twitter: https://twitter.com/fraudstersLPNInstagram: https://www.instagram.com/fraudsterslpn/YouTube: https://www.youtube.com/channel/UCQwl8sDTVEAxhwJdYgm-yrgIntro Music Credit and Sound Fx:https://twitter.com/gograntgordonSeason Cover Art by:https://comedyartwork.com/

Movie Bets, Country Lukes, Pinocchio's Drawrings, Paramore's Savvy. Nick Turner is back! Check out his limited series The Show Me The Money Podcast!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest deejay is Joshua Bruner. I had the good fortune of meeting Joshua through Nick Turner, AKA Tyresta, when I asked him who he thought would share a mix on Soundwave. Nick's music and his mix for Soundwave are lovely. When Nick suggested Joshua, I was immediately on board. I ask every guest deejay on Soundwave who would share a mix on the show. It's a simple thing, but over the last few years, it has led to meeting some extremely talented people and turned me on to fantastic music that I am confident I would've never discovered on my own, let alone singular mixes curated by each guest deejay. Joshua's mix is yet another example. I don't know any of the musicians he included in his playlist. That's no slight to them. They're all fantastic. There's just too much music to listen to. Joshua has selected breathtaking tracks for his mix. I'm listening to it as I write this. His mix seamlessly blends with my night of rain pattering on my roof and the whoosh of jets flying to a nearby airport. It's quite the experience, which is why I'm always asking who should guest deejay on Soundwave. Joshua has some words about his mix below. Join us next week when our guest deejay will be Enrico Coniglio. See you then. This episode will be released just a few days before my 43rd birthday! Sometime in January or February, I expect to release an album on vinyl in collaboration with Alyssa Miserendino, someone I would highly recommend for a future mix. I'm excited about this record because it includes field recordings she captured in South America with Gordon Hempton, aka The Sound Tracker. I used a brainwave sonification technique using an EEG to trigger selected samples from their recordings of a unique bird called the Oropendola. David Behrman “Music with Melody-Driven Electronics” Gordon Hempton “Om Telephone Wire” Klaus Wiese “Mystic Landscapes II” Alvin Lucier “B. 2” Gordon Hempton “Back of the Cave” David Behrman “Music with Melody-Driven Electronics" --- Send in a voice message: https://anchor.fm/soundwavemix/message

Nick Turner joins The Great Battlefield podcast to talk about his career working to reform our justice system and now serving as President of the Vera Institute for Justice, where they're working to end mass incarceration and strengthen communities.

Nick Turner, Bloomberg Senior Tech Editor, discusses Apple easing its grip on its app store. He spoke with hosts Bryan Curtis and Rishaad Salamat on Bloomberg Radio.See omnystudio.com/listener for privacy information.

With the U.S. midterm elections just behind us, to continue Off-Kilter's ongoing series of conversations about the limiting beliefs that we as a collective must release and replace to pave the way for economic liberation, Rebecca sat down with Nick Turner—president and director of the Vera Institute for Justice—to unpack two of the most toxic limiting beliefs in American politics that flared up dramatically in the recent midterms: the notion that you have to be “tough on crime” to win political office, and that safety requires tough on crime policies. They had a far-ranging conversation about expanding consciousness around America's broken criminal legal system in recent years—and how safety and justice can actually go hand in hand. For more: Learn more about the Vera Institute for Justice's work here Dig into Vera's polling on crime and safety narratives and the midterms here Follow Nick (@nickturner718) and the Vera Institute (@verainstitute) on Twitter

George Conway stops by to react to Trump's 2024 presidential announcement.  Ambassador Gordon Sondland stops by to talk to us about him time under Trump and his new book The Envoy. Then we're joined by Nick Turner President of the Vera Institute, who will talk to us about crime and the effect it had on the midterms. See omnystudio.com/listener for privacy information.

Orange County was one of the most popular drum brands in the world in the early 2000's, and I am joined today by Corey Manske and Nick Turner who were some of the original builders during the heyday. Jarrod Fallon is a restorer and buff on all things OCDP and he co-hosts the episode with me. This is a follow up to the first Orange County episode with Jarrod and Michael Kelley and we answer tons of great questions that were submitted by fans of the brand. This is a fun one with a bunch of great behind the scenes stories that makes you feel like you are a part of the original crew building one of a kind drums for greats like Travis Barker, John Otto, Adrien Young, Chad Sexton and many more. -Follow Corey on social media at @coreymanske, Nick Turner at @dagnastee, and Jarrod Fallon at @ghostnote_percussion. -Big thanks to Michael Kelley for sponsoring this episode. Check out everything he has for sale at www.kelleydrums.com -Here is a link to the original OCDP episode with Jarrod Fallon and Michael Kelley: https://www.drumhistorypodcast.com/post/ep-163-the-history-of-orange-county-drums-with-michael-kelley-and-jarrod-fallon. **DRUM HISTORY MERCH** https://www.teepublic.com/stores/drum-history-podcast?ref_id=26024 ** CHECK OUT MY GEAR ON SWEETWATER ** https://imp.i114863.net/yRYRGN ** 30 DAY FREE DRUMEO TRIAL ** https://drumeo.pxf.io/c/3607735/1268414/14652 **JOIN PATREON** https://www.patreon.com/drumhistorypodcast **I record interviews with Riverside.FM - I highly recommend it. Here is my affiliate link: https://riverside.fm/?via=bart-vanderzee

Over the weekend, 20 Russian missiles hit civilian areas of Zaporizhzhia, killing at least 13 people and injuring 60 more. These air strikes followed an explosion on Saturday on the bridge between Russia and Crimea, which has both economic and symbolic importance.New York City Mayor Eric Adams declared a state of emergency on Friday after the city's primary shelter system became overloaded, due in part to the influx of asylum seekers from Latin America. We discuss what Adams is and isn't doing to help people in New York City find shelter... and the efforts of Republican governors like Texas's Greg Abbott and Arizona's Doug Ducey to exacerbate the city's houselessness crisis.And in headlines: Nationwide protests in Iran over the death of Mahsa Amini entered their fourth week, Harvey Weinstein's Los Angeles trial starts today, and a NLRB judge ruled that a Michigan Starbucks illegally fired one of its baristas for union organizing. Show Notes:Vote Save America: Every Last Vote – https://votesaveamerica.com/every-last-vote/Thanks to Nick Turner for writing on this episode!Crooked Coffee is officially here. Our first blend, What A Morning, is available in medium and dark roasts. Wake up with your own bag at crooked.com/coffeeFollow us on Instagram – https://www.instagram.com/whataday/For a transcript of this episode, please visit crooked.com/whataday

In episode 1344, Jack and Miles are joined by comedian and co-host of Get Rich Nick, Nick Turner, to discuss… Fascism Has a Good Day In Brazil And the Market Approves, Majorly Tainted Goon is Now Just Leaning into the Paranoia, MORE OBSCURE SPORTS CHEATING and more! Fascism Has a Good Day In Brazil And the Market Approves Brazil girds for tight runoff vote after Bolsonaro's strong showing MORE OBSCURE SPORTS CHEATING LISTEN: Don't Say No by Speed, Glue & ShinkiSee omnystudio.com/listener for privacy information.

Nick Turner from PowerofTheFuture.com joins the show to discuss inflation, energy, the wind and solar agenda, and the lack of practicing what you preach by Politicians.

In episode 52 Clarita chats with pal Nick Turner from Sub Pop Records. Nick is a Seattle musician, record collector, co-founder of Sonic Reducer on KEXP, currently at Sub Pop, and all around great human. He talks about his bands, working at record stores, his college radio show, starting a punk show in Seattle, The Vera Project, Sub Pop Singles Club, terrifying Beatles, confusing covers, design pranks, and way more! Thanks for listening.Follow the new Instagram account: @designfreakspod  ~~Designfreakspodcast.comRuinousmedia.com~~NIck's Bands:Private Room https://ironlungrecords.bandcamp.com/album/forever-and-ever-lp-lungs-084Dead Language https://ironlungrecords.bandcamp.com/album/dead-language-lp-lungs-020WALLS https://ironlungrecords.bandcamp.com/album/the-future-is-wide-open-lp-lungs-028Society Nurse https://ironlungrecords.bandcamp.com/album/society-nurse-lp-lungs-019Cold Sweat https://ironlungrecords.bandcamp.com/album/blinded-remastered-lp-lungs-095-2~~Donate to help with recording costs Thank you!~~Theme music: "Jet in Jungle" by Damaged Bug, courtesy of John DwyerSupport the show

Thicc O'Clock. Heckling Woody Allen. White Toy Summah. Beach vs Space. Wilmington North Carolina tour. Comedian Nick Turner is back on the charts! See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

KATG regular Nick Turner catches us up on his life, marriage, and son, and he helps dive into hot topics such as Megan Fox and Machine Gun Kelly's blood rituals, the true story behind the horror movie Hostel, Will Smith's spiritual tour, and Nicolas Cage's meta comedy.

KATG regular Nick Turner catches us up on his life, marriage, and son, and he helps dive into hot topics such as Megan Fox and Machine Gun Kelly's blood rituals, the true story behind the horror movie Hostel, Will Smith's spiritual tour, and Nicolas Cage's meta comedy.